Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A drug with hyperglycemic and antihypertensive action via peripheral vasodilatation. Indicated orally (2 to 3 daily doses) in the treatment of unresponsive hyperglycemia by hyperinsulinism and intravenously in hypertensive crises. Its use is authorized in the neonatal and infant period.
It is excreted in breast milk in small amounts, but could be clinically significant. (Saito 2022)
A newborn partially breastfed by a mother taking diazoxide orally had no clinical problems or alterations in blood glucose at one month of life. (Saito 2022)
If Diazoxide is taken during lactation, it is advisable to monitor the infant's blood glucose regularly.
Pending further published data on this drug in relation to lactation, safer known alternatives may be preferable (Schaefer 2015 p790), especially during the neonatal period and in case of prematurity.